European trial on reduction of cardiac events with perindopril in stable coronary artery disease

1. EUROPA Trial European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003

2. EUROPA Trial 12,218 low-risk patients with stable coronary artery disease Randomized, double-blind, placebo-controlled • Perindopril • 8 mg/day • n=6,110 • Placebo • n= 6,108 • Endpoints (follow-up mean 3.4 years): • Primary – Composite of CV mortality, nonfatal MI, and cardiac arrest • Secondary – Composite of total death, nonfatal MI, and cardiac arrest; heart failure; revascularization (PCI/CABG); and stroke European Society of Cardiology 2003

3. EUROPA Trial CV Mortality p=0.107 CV death/non-fatal MI/ cardiac arrest p=0.0003 European Society of Cardiology 2003

4. EUROPA Trial • Among patients with stable coronary artery disease, treatment with the ACE-I perindopril was associated with a reduction in the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest compared with placebo • ACE inhibitors have previously been shown to be effective in other patient populations, including heart failure, left ventricular dysfunction, and high-risk coronary artery disease patients • The present trial is the largest to show a benefit in stable, low-risk CAD patients